Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

NCT00167986 · clinicaltrials.gov ↗

COMPLETED

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Escherichia Coli Infections
Klebsiella Infections

Interventions

DRUG: vancomycin-resistant enterococci and ESBL

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer